Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Total Non-Current Liabilities (2017 - 2025)

Eton Pharmaceuticals' Total Non-Current Liabilities history spans 3 years, with the latest figure at $60.7 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 21.77% to $60.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.7 million, a 21.77% increase, with the full-year FY2025 number at $60.7 million, up 21.77% from a year prior.
  • Total Non-Current Liabilities hit $60.7 million in Q4 2025 for Eton Pharmaceuticals, down from $77.4 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for ETON hit a ceiling of $77.4 million in Q3 2025 and a floor of $16.3 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $55.5 million across 3 years, with a median of $58.1 million in 2025.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 206.62% in 2024 and later increased 21.77% in 2025.
  • Tracing ETON's Total Non-Current Liabilities over 3 years: stood at $16.3 million in 2023, then skyrocketed by 206.62% to $49.9 million in 2024, then rose by 21.77% to $60.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ETON at $60.7 million in Q4 2025, $77.4 million in Q3 2025, and $73.4 million in Q2 2025.